Idorsia AG faces significant financial challenges despite advancements in drug development, with its share price plummeting over 56% to EUR 1.446 in the past year. The company recently secured US approval for the antihypertensive drug aprocitentan, which could generate essential revenue. However, the financial outlook remains precarious as CEO Jean-Paul Clozel has yet to announce concrete plans for securing fresh capital.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
